224 related articles for article (PubMed ID: 9554590)
21. [Irinotecan pharmacokinetics].
Chabot GG; Robert J; Lokiec F; Canal P
Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Ma MK; Zamboni WC; Radomski KM; Furman WL; Santana VM; Houghton PJ; Hanna SK; Smith AK; Stewart CF
Clin Cancer Res; 2000 Mar; 6(3):813-9. PubMed ID: 10741701
[TBL] [Abstract][Full Text] [Related]
23. Phase I and pharmacokinetic trial of weekly CPT-11.
Rothenberg ML; Kuhn JG; Burris HA; Nelson J; Eckardt JR; Tristan-Morales M; Hilsenbeck SG; Weiss GR; Smith LS; Rodriguez GI
J Clin Oncol; 1993 Nov; 11(11):2194-204. PubMed ID: 8229134
[TBL] [Abstract][Full Text] [Related]
24. Intrathecal administration of topotecan in nonhuman primates.
Blaney SM; Cole DE; Godwin K; Sung C; Poplack DG; Balis FM
Cancer Chemother Pharmacol; 1995; 36(2):121-4. PubMed ID: 7767947
[TBL] [Abstract][Full Text] [Related]
25. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.
Hamada A; Aoki A; Terazaki H; Ito K; Yokoo K; Sasaki Y; Saito H
Ther Drug Monit; 2005 Aug; 27(4):536-8. PubMed ID: 16044114
[TBL] [Abstract][Full Text] [Related]
27. Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks.
Minami H; Fujii H; Igarashi T; Itoh K; Tamanoi K; Oguma T; Sasaki Y
Clin Cancer Res; 2001 Oct; 7(10):3056-64. PubMed ID: 11595695
[TBL] [Abstract][Full Text] [Related]
28. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
Mick R; Gupta E; Vokes EE; Ratain MJ
J Clin Oncol; 1996 Jul; 14(7):2012-9. PubMed ID: 8683231
[TBL] [Abstract][Full Text] [Related]
29. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
[TBL] [Abstract][Full Text] [Related]
30. Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis.
Sparreboom A; de Jonge MJ; Punt CJ; Loos WJ; Nooter K; Stoter G; Porro MG; Verweij J
Drug Metab Dispos; 1999 Jul; 27(7):816-20. PubMed ID: 10383926
[TBL] [Abstract][Full Text] [Related]
31. Biliary excretion of irinotecan and its metabolites.
Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
[TBL] [Abstract][Full Text] [Related]
32. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.
Haaz MC; Rivory LP; Riché C; Robert J
Naunyn Schmiedebergs Arch Pharmacol; 1997 Aug; 356(2):257-62. PubMed ID: 9272733
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
Canal P; Gay C; Dezeuze A; Douillard JY; Bugat R; Brunet R; Adenis A; Herait P; Lokiec F; Mathieu-Boue A
J Clin Oncol; 1996 Oct; 14(10):2688-95. PubMed ID: 8874328
[TBL] [Abstract][Full Text] [Related]
34. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.
Lin LC; Wang MN; Tsai TH
Chem Biol Interact; 2008 Aug; 174(3):177-82. PubMed ID: 18579105
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
de Jonge MJ; Verweij J; de Bruijn P; Brouwer E; Mathijssen RH; van Alphen RJ; de Boer-Dennert MM; Vernillet L; Jacques C; Sparreboom A
J Clin Oncol; 2000 Jan; 18(1):195-203. PubMed ID: 10623710
[TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.
Baker SD; Heideman RL; Crom WR; Kuttesch JF; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 1996; 37(3):195-202. PubMed ID: 8529278
[TBL] [Abstract][Full Text] [Related]
37. Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan.
Guemei AA; Cottrell J; Band R; Hehman H; Prudhomme M; Pavlov MV; Grem JL; Ismail AS; Bowen D; Taylor RE; Takimoto CH
Cancer Chemother Pharmacol; 2001 Apr; 47(4):283-90. PubMed ID: 11345644
[TBL] [Abstract][Full Text] [Related]
38. Salivary drug monitoring of irinotecan and its active metabolite in cancer patients.
Takahashi T; Fujiwara Y; Sumiyoshi H; Isobe T; Yamaoka N; Yamakido M
Cancer Chemother Pharmacol; 1997; 40(5):449-52. PubMed ID: 9272124
[TBL] [Abstract][Full Text] [Related]
39. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies.
Escoriaza J; Aldaz A; Castellanos C; Calvo E; Giráldez J
J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):159-68. PubMed ID: 10821401
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
